Gluformin G 2 New Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, acts by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The combination therapy offers complementary mechanisms of action, providing improved glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Gluformin G 2 New Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia. Regular monitoring of blood glucose, renal function, and periodic assessment of hematologic parameters are recommended during therapy. This combination tablet offers the convenience of dual-action glucose regulation, facilitating improved patient adherence and glycemic outcomes in type 2 diabetes management.